This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
The improvement in forced expiratory volume in one second (FEV1) and the area under the FEV1 response time curve from time 0 -4 hours (FEV1 AUC 0-4) was significantly greater for the combination of albuterol plus ipratropium than either albuterol or ipratropium alone on all test days.
The mean (FEV1 AUC 0-4) for albuterol, ipratropium and ipratropium plus albuterol was: The inclusion of ipratropium in the pharmacologic treatment regimen was also associated with a lower rate of exacerbations. 62% of patients receiving albuterol experienced exacerbations compared to 45% receiving ipratropium and 44% receiving ipratropium plus albuterol, (p < 0.05). Albuterol patients had 770 patient days of exacerbations compared to 504 patient days for ipratropium patients and 554 for combination patients, (p < 0.05). Increased exacerbations in the albuterol only group were associated with a greater total number of hospital days (103 days) than albuterol plus ipratropium (46 days) and ipratropium alone (20 days), (p<0.05) and greater antibiotic and corticosteroid use.
Clinical conclusions
The inclusion of ipratropium in a pharmacological treatment regimen is associated with a lower rate of exacerbations.
Measure of benefits used in the economic analysis
Changes in forced expiratory volume (FEV1) and disease exacerbation were the benefit measures.
Direct costs
Quantities and costs were analysed separately. Only health service costs were considered: number and length of acute pulmonary exacerbations of COPD, the number and length of hospitalisations due to exacerbations, and the number of patient days of increased doses or additions of corticosteroids and antibiotics. The basis for the acquisition costs of the drugs was the 1998 PC-Price Chek average wholesale price. The price date was 1998.
Statistical analysis of costs
A statistical analysis (analysis of covariance) was performed.
